Insights
Search Results
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises Zscaler on Acquisition of SquareX
On February 05, 2026, Zscaler, a leader in cloud security, announced it has acquired SquareX, to further extend Zero Trust capabilities into the browser for the AI era. This acquisition will help redefine browser security, allowing organizations to embed lightweight extensions into any browser, providing increased security, and eliminating the need for third-party browsers. The acquisition closed on February 5, 2026. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Zscaler on the transaction.
Client Highlights
11.03.25
Wilson Sonsini Advises Pear Suite on $7.6 Million Series A Funding
On October 14, 2025, Pear Suite, a digital health company empowering community health workers, announced that it has raised $7.6 million in Series A funding. The investment round is led by Rock Health Capital and Nexxus Holdings, with support from Mucker Capital, Enable Ventures, The SCAN Foundation, Acumen America, Impact Engine, and the California Health Care Foundation. Wilson Sonsini Goodrich & Rosati advised Pear Suite on the transaction.
Client Highlights
10.31.25
Firm Advises Curve Biosciences on $40 Million Funding
On October 29, 2025, Curve Biosciences, the Whole-Body Intelligence™ company, announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others. The funding will advance the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform to transform chronic disease monitoring.
Wilson Sonsini Goodrich & Rosati advised Curve on the transaction. The team included Elton Satusky, Roy Argand, Davelyn Bulovas, and Isaac Reed.
Wilson Sonsini Goodrich & Rosati advised Curve on the transaction. The team included Elton Satusky, Roy Argand, Davelyn Bulovas, and Isaac Reed.
Client Highlights
6.26.25
Wilson Sonsini Advises Materna Medical on $20 Million Series B2
On June 17, 2025, Materna Medical, Inc., a leading innovator in women’s pelvic health solutions, announced the completion of a recent close within an ongoing $20 million Series B2 financing round. The round welcomed new funds GLIN Impact Capital, Wealthing VC Club, and Citrine Angels, and was led by InnovaHealth Partners and other key existing investors Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, and Golden Seeds. Wilson Sonsini Goodrich & Rosati advised Materna Medical on the transaction.
Client Highlights
5.21.25
Wilson Sonsini Advises Halo Labs on Acquisition by Waters
On May 21, 2025, Waters Corporation announced that it acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. Wilson Sonsini Goodrich & Rosati advised Halo Labs on the transaction.
Client Highlights
1.15.25
Wilson Sonsini Advises Zeto, Inc. on $31 Million Series B
On January 8, 2025, Zeto, Inc., a medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and AI-driven cloud platform, announced the recent closing of a $31 million funding round led by MindWorks Global. The new funding will enable Zeto to expand its commercial and operational teams, drive further growth, and strengthen ongoing research and development efforts.
Client Highlights
12.12.24
Wilson Sonsini Advises Axiado Corporation on $60 Million Series C Funding
On December 4, 2024, Axiado Corporation, a pioneer in hardware anchored platform security, announced it successfully raised $60 million in an oversubscribed Series C funding round. The round was led by Maverick Silicon with participation from Samsung Catalyst Fund, Atreides Management, and Crosslink Capital. Wilson Sonsini Goodrich & Rosati advised Axiado Corporation on the transaction.
This investment will fuel the company’s rapid growth and continued innovation in AI-driven cybersecurity technologies that are redefining platform security and energy efficiency for accelerated computing in AI data centers. Axiado will use the funding to drive continued innovation, strengthen strategic partnerships with leading platform vendors like NVIDIA, AMD, Intel, and Arm, and accelerate go-to-market initiatives with OEM and ODM partners to drive Axiado solutions into the data centers.
This investment will fuel the company’s rapid growth and continued innovation in AI-driven cybersecurity technologies that are redefining platform security and energy efficiency for accelerated computing in AI data centers. Axiado will use the funding to drive continued innovation, strengthen strategic partnerships with leading platform vendors like NVIDIA, AMD, Intel, and Arm, and accelerate go-to-market initiatives with OEM and ODM partners to drive Axiado solutions into the data centers.
Client Highlights
7.16.24
Wilson Sonsini Advises Digestiva on $18.4 Million Series A Financing
On July 15, 2024, Digestiva, a leading food biotech company, successfully closed its Series A equity financing round, raising $18.4 million. The round was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments, and existing investors The March Fund and Astanor. Digestiva's groundbreaking enzyme technology platform was initially discovered by co-founder Dr. Wilson Mak, in the lab of UC Davis faculty member Dr. Justin Siegel, a global leader in enzyme discovery, development, and design. Wilson Sonsini Goodrich & Rosati represented Digestiva in the transaction.
Client Highlights
12.18.23
Wilson Sonsini Advises Visant Medical on Acquisition By Nordic Pharma
On December 18, 2023, Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V. (Nordic Pharma), announced the completion of its acquisition of Visant Medical, Inc., a leader in medical technology innovation in Dry Eye Disease (DED). Wilson Sonsini Goodrich & Rosati advised Visant Medical on the transaction.
Client Highlights
11.07.22
Wilson Sonsini Advises project44 on $80 Million Funding Round
On November 3, 2022, project44, the leading supply chain visibility platform, announced that it raised an $80 million funding round led by sustainable investment management firm Generation Investment Management and Denmark-based, privately held investment company A.P. Moller Holding. CMA CGM also joined the round, along with previous investors Goldman Sachs Asset Management, TPG, Emergence Capital, Chicago Ventures, Sapphire, 8VC, Sozo Ventures, and Omidyar Technology Ventures. Wilson Sonsini Goodrich & Rosati advised project44 on the transaction.
Today, project44 helps more than 1,200 companies achieve predictability, resilience, and sustainability across their global supply chains. Customers use project44 to ensure on-time delivery of shipments, proactively address supply chain disruptions, and move goods more efficiently. The proceeds from the funding will drive several key initiatives, including measuring and mitigating supply chain emissions globally, across all modes of transportation.
The Wilson Sonsini team that advised project44 on the transaction included:
Corporate
Michael Coke
Travis Scheft
Roy Argand
TJ Tingjie Li
Samuel Silverstein
Henry Yen
Today, project44 helps more than 1,200 companies achieve predictability, resilience, and sustainability across their global supply chains. Customers use project44 to ensure on-time delivery of shipments, proactively address supply chain disruptions, and move goods more efficiently. The proceeds from the funding will drive several key initiatives, including measuring and mitigating supply chain emissions globally, across all modes of transportation.
The Wilson Sonsini team that advised project44 on the transaction included:
Corporate
Michael Coke
Travis Scheft
Roy Argand
TJ Tingjie Li
Samuel Silverstein
Henry Yen